Nathan D. Jorgensen - Oct 3, 2025 Form 4 Insider Report for Voyager Therapeutics, Inc. (VYGR)

Role
Chief Financial Officer
Signature
/s/ Robin Swartz, as Attorney-in-Fact for Nathan D. Jorgensen
Stock symbol
VYGR
Transactions as of
Oct 3, 2025
Transactions value $
-$36,643
Form type
4
Date filed
10/7/2025, 04:30 PM
Previous filing
Feb 24, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Jorgensen Nathan D. Chief Financial Officer C/O VOYAGER THERAPEUTICS, INC., 75 HAYDEN AVENUE, LEXINGTON /s/ Robin Swartz, as Attorney-in-Fact for Nathan D. Jorgensen 2025-10-07 0001842523

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VYGR Common Stock Sale -$36.6K -7.67K -5.83% $4.78 124K Oct 3, 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter adopted by the reporting person on May 9, 2025 effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on October 3, 2025. The sales do not represent a discretionary trade by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.74 to $4.85, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.